

Project Summary Information

	Date of Document Preparation/Updating: September 30, 2024		
Project Name	Support for COVID-19 Vaccine Delivery in Mongolia under the Asia Pacific Vaccine Access Facility		
Project Number	P000519		
AllB member	Mongolia		
Sector/Subsector	Public Health		
Status of	Approved		
Financing			
Project Description	The Project was approved by AIIB's Board of Directors on June 10, 2021 to support the procurement and delivery of Covid-19 vaccines under the COVID-19 Crisis Recovery Facility of AIIB. It is co-financed with the Asian Development Bank (ADB) through ADB's Asia Pacific Vaccine Access Facility (APVAX).		
	The Project has provided the Government of Mongolia (GOM) with immediate financing support to purchase safe and effective vaccines against COVID-19 through APVAX. The Project has assisted the GOM in direct procurement of APVAX-eligible vaccines from manufacturers as well as international logistics to Mongolia. Through providing timely access to eligible COVID-19 vaccines, the Project helped contribute to containment of the pandemic and supporting economic and social recovery in the country. Additionally, it has supported the implementation of the National Deployment and Vaccination Plan (NDVP) in Mongolia, contributing to the GOM's efforts to immunize at least 30% of the population.		
	At the GOM's request, the Project scope is proposed to be expanded to support the GOM in additional activities including the re-establishment of essential health care services disrupted during the COVID-19 and the enhancement of health security preparedness. This will enable Mongolia to transition more effectively towards a robust post-COVID-19 recovery. Furthermore, it will facilitate increased access to primary health care and improve the operational efficiency of primary health care services across Mongolia. These additional activities will be financed out of undisbursed loans of AIIB and ADB.		
Objective	With the proposed change to Project scope, the Project's objectives will be: (i) to increase availability of the eligible vaccines for the priority population, as defined by the GOM in its NDVP, and (ii) to re-establish essential health care services disrupted by COVID-19.		
Expected Results	With the proposed change to Project scope, the expected outcome of the Project will be the priority population vaccinated against COVID-19 with re-established primary health care services. The Project outputs will be: (i) COVID-19 vaccines for priority population efficiently procured and delivered, (ii) primary health care services for noncommunicable diseases disrupted by COVID-19 re-established, and (iii) awareness on COVID-19 vaccination and delivery enhanced.		

Environmental and	ADD Catagory C for Environm	nent C for Involuntary Becettleme	ant and C for Indigenous Beenles (equivalent to Catagory C		
	ADB Category C for Environment, C for Involuntary Resettlement and C for Indigenous Peoples (equivalent to Category C				
Social Category	if AIIB's ESP were applicable).				
Environmental and	The loan will continue to be co-financed with ADB as lead co-financier, and the Project's environmental and social (ES)				
Social Information	risks and impacts have been assessed in accordance with ADB's Safeguard Policy Statement (SPS). To ensure a harmonized approach to addressing the ES risks and impacts of the Project, and as permitted under AllB's Environmental and Social Policy (ESP), ADB's SPS will apply to the Project in lieu of AllB's ESP. AllB has reviewed ADB's SPS and is satisfied that: (i) it is consistent with AllB's Articles of Agreement and materially consistent with the provisions of AllB's ESP, including the Environmental and Social Exclusion List (ESEL) and the relevant Environmental and Social Standards (ESSs); and (ii) the monitoring procedures that are in place are appropriate for the Project. As the proposed change to the Project scope will not entail any civil works or activities which may cause adverse impacts on the environment, and do not involve any land acquisition or involuntary resettlement impacts, the Project's E&S categorization remains unchanged as Category C for Environment, Involuntary Resettlement, and Indigenous Peoples. The Project was originally categorized as "some gender elements" by ADB as it was expected to significantly benefit				
Cost and	women and children by providing access to COVID-19 vaccinations. The gender targets have already been met.				
	The total cost is USD43.82 million. The financing plan is as follows.				
Financing Plan	Co-financiers	Amount (USD million)	٦		
		Amount (USD million)	_		
	AIIB	21			
	ADB	19			
	Government of Mongolia	3.82			
	Total	43.82			
Borrower	Mongolia				
Implementing	Ministry of Health and the Health Insurance General Office				
Entity/Sponsor					
Estimated date of	December 2024				
loan closing					

Contact Points:	AIIB	ADB	Borrower	Implementation	
				Organization/Sponsor	
Name	Xiang Li	Najibullah Habib	Batkhuu Idesh	Yanjmaa Binderiya	
Title	Investment Solutions	Senior Health Specialist	Director General, Development	Director of Division of International	
	Specialist		Financing Department,	Cooperation, Ministry of Health	
			Ministry of Finance		
Email Address	xiang.li1@aiib.org	nhabib@adb.org	Batkhuu_i@mof.gov.mn	yanjmaa@moh.gov.mn	
Date of Concept	May 19, 2021				
Decision					
Date of Appraisal	May 19, 2021				
Decision					
Date of Financing	June 10, 2021				
Approval					

Independent	As noted above, ADB's SPS will apply to this Project instead of AIIB's ESP. Pursuant to AIIB's agreement with			
Accountability	ADB, AIIB will rely on ADB's Independent Accountability Mechanism, the Accountability Mechanism, to handle			
Mechanism	complaints relating to ES issues that may arise under the Project. Consequently, in accordance with AIIB's Policy on the Project affected People's Mechanism (PPM), submissions to the PPM under this Project will not be eligible for consideration by the PPM. Information on ADB's Accountability Mechanism is available at: https://www.adb.org/site/accountability-mechanism/main.			